Patents Examined by Enrique D. Longton
-
Patent number: 5948668Abstract: The subject invention provides a method of producing enzymatically active CPB which comprises treating a recombinant cell containing DNA encoding ProCPB, so that the DNA directs expression of the ProCPB, recovering from the cell the ProCPB so expressed, treating the recovered ProCPB under conditions permitting folding of the ProCPB, subjecting the folded ProCPB to enzymatic cleavage to produce enzymatically active CPB and purifying the enzymatically active CPB.Type: GrantFiled: January 13, 1997Date of Patent: September 7, 1999Assignee: Bio-Technology General Corp.Inventors: Jacob Hartman, Netta Fulga, Simona Mendelovitch, Marian Gorecki
-
Patent number: 5948756Abstract: A lipoprotein particle and a therapeutic lipoprotein composition are disclosed. The lipoprotein particle consists essentially of lecithin phospholipids with low phase transition temperatures and human apoproteins A and C. A therapeutic composition for therapeutic administration to a subject, comprising the lipoprotein particles of the invention, is also disclosed. The composition is useful is treating disease conditions associated with elevated serum Lp(a) levels, as well as hypertension and acute renal failure.Type: GrantFiled: August 31, 1995Date of Patent: September 7, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda, Tova Chajek
-
Patent number: 5948634Abstract: The present invention is directed to recombinant hosts expressing novel proteins associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins. This invention is also directed to substantially pure neural thread protein, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code for neural thread proteins in gene therapy.Type: GrantFiled: November 14, 1994Date of Patent: September 7, 1999Assignee: The General Hospital CoporationInventors: Suzanne de la Monte, Jack R. Wands
-
Patent number: 5948888Abstract: The present invention is directed to recombinant hosts expressing novel proteins associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins. This invention is also directed to substantially pure neural thread protein, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code for neural thread proteins in gene therapy.Type: GrantFiled: May 30, 1995Date of Patent: September 7, 1999Assignee: The General Hospital CorporationInventors: Suzanne de la Monte, Jack R. Wands
-
Patent number: 5945321Abstract: Human UCE 7, UCE 8 and UCE 9 polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods of utilizing such polypeptides for the treatment of the porliferation of malignant cells. Antagonists against such polypeptides and their uses as a therapeutic to treat Alzheimer's disease, atrophying skeletal muscle, African Swine Fever Virus and apoptotic cell death are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in UCE 7, 8 and 9 nucleic acid sequences and to the concentration of polypeptides encoded by such sequences.Type: GrantFiled: October 2, 1997Date of Patent: August 31, 1999Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Mark D. Adams
-
Patent number: 5939306Abstract: The present invention relates to histidine kinases, including osmosensing fungal histidine kinases. In particular, the present invention provides amino acid and nucleic acid sequences of fungal histidine kinases from organisms such as Candida (e.g., C. albicans) and Neurospora (e.g., N. crassa). The present invention further provides compositions and methods for the development of antifungal compounds.Type: GrantFiled: April 16, 1997Date of Patent: August 17, 1999Assignees: University Technology Corporation, California Institute of TechnologyInventors: Lisa A. Alex, Melvin I. Simon, Claude Selitrennikoff, Jacqueline Agnan
-
Patent number: 5928892Abstract: Variant complement proteins that are modified in their complement-mediated activity are provided, along with methods for their preparation, and their potential uses. The modifications comprise amino acid substitutions in regions of the complement proteins that contain certain motifs also present in homologous proteins. The amino acid substitutions and their effect on the complement activity of the modified protein are also provided.Type: GrantFiled: July 26, 1996Date of Patent: July 27, 1999Assignee: Washington UniversityInventors: Dennis E. Hourcade, Teresa J. Oglesby
-
Patent number: 5928894Abstract: The invention provides a human actVA-ORF4-like protein (A-ORFP) and polynucleotides which identify and encode A-ORFP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of A-ORFP.Type: GrantFiled: September 3, 1997Date of Patent: July 27, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Tom Tang, Neil C. Corley, Purvi Shah
-
Patent number: 5925739Abstract: The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIII or factor IX and use thereof for manufacture of a medicament for treating haemophilia A or B. The formulation comprises coagulation factor VIII or factor IX with an activity of at least 200 IU/ml and an additive increasing the bio-availability of factor VIII or factor IX. Tests with factor VIII gives a therapeutic level of active factor VIII in the blood stream for a surprisingly long period of time after subcutaneous, intramuscular or intradermal administration. The factor VIII is suitably a highly purified recombinant factor VII, and preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.Type: GrantFiled: September 17, 1996Date of Patent: July 20, 1999Assignee: Pharmacia & Upjohn ABInventors: Jack Spira, Lars Widlund, Thomas Osterberg, Brita Sjostrom, Marianne Mikaelsson
-
Patent number: 5922563Abstract: Disclosed are novel Trichomonas vaginalis adhesin cDNA and amino acid sequences, vectors and host cells. Also disclosed is an iron up-regulated promoter sequence. Methods of differential expression of a gene in the presence of iron and methods of inhibiting Trichomonas cytoadherence are also disclosed.Type: GrantFiled: July 20, 1995Date of Patent: July 13, 1999Assignee: Board of Regents, The University of Texas SystemInventor: John F. Alderete
-
Patent number: 5919654Abstract: A secretion signal gene having a base sequence encoding a polypeptide functional as a secretion signal in fission yeast Schizosaccharomyces pombe (hereinafter referred to as S. pombe), an expression vector having the gene and a foreign protein structural gene, a multicloning vector for construction of the expression vector which has the secretion signal gene, and efficient secretory production of the foreign protein structural gene product by S. pombe and the like.Type: GrantFiled: October 2, 1996Date of Patent: July 6, 1999Assignee: Asahi Glass Company Ltd.Inventors: Yuko Hama, Hideki Tohda, Hiroko Tsukamoto, Kiyokazu Nikaido, Hiromichi Kumagai
-
Patent number: 5919659Abstract: The invention provides a new human phosphatidylinositol transfer protein gamma (PITP.gamma.) and polynucleotides which identify and encode PITP.gamma.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PITP.gamma..Type: GrantFiled: June 11, 1997Date of Patent: July 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5914311Abstract: A method of reducing serum Lp(a) concentration in a subject is accomplished by administration of liposomes. A suspension of small, unilamellar vesicles composed primarily of phosphatidylcholine phospholipids is administered parenterally to a subject having or at risk for developing a disease condition associated with an elevated serum Lp(a) concentration. The liposomes are infused over a period of time such that a significant drop in serum Lp(a) concentration is observed.Type: GrantFiled: May 19, 1998Date of Patent: June 22, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda, Tova Chajek
-
Patent number: 5910425Abstract: Microbial strains capable of producing enhanced levels of sphingosine, dihydrosphingosine, phytosphingosine and/or derivatives thereof are disclosed. Additionally, there are disclosed methods based on mutagenesis, or other selection techniques, whereby such strains can be produced. As a preferred example thereof, mutant strains of Pichia are provided that are capable of producing about 50% more of such compounds than wild type strains.Type: GrantFiled: May 3, 1996Date of Patent: June 8, 1999Assignee: Gist-Brocades, N.V.Inventors: Lex De Boer, Ingrid Francisca Caroline Van Der Wildt
-
Patent number: 5908827Abstract: A new protein is described obtainable from urine through an extraction and purification process by ion-exchange chromatography and high resolution chromatography.Type: GrantFiled: January 22, 1996Date of Patent: June 1, 1999Assignee: Applied Research Systems ARS Holding N.V.Inventor: Antonino Sirna
-
Patent number: 5895747Abstract: The Tax protein of Human T Cell Leukemia Virus Type 1 (HTLV-I) transcriptionally activated the HTLV-I promoter through binding sites for ATF, a family of cellular bZIP transcription factors. In this disclosure, it is reported that Tax dramatically increases the in vitro DNA binding activity of multiple ATF proteins. Tax also stimulates DNA binding of related bZIP proteins but does not affect the activity of proteins lacking a bZIP domain. The increased DNA binding activity occurs by a novel mechanism in which Tax promotes homodimerization in the absence of DNA. The elevated concentration of the bZIP homodimer results in increased DNA binding.Type: GrantFiled: August 24, 1995Date of Patent: April 20, 1999Assignee: University of Massachusetts Medical CenterInventors: Michael R. Green, Susanne Wagner
-
Patent number: 5892005Abstract: The invention provides high and low molecular weight fraction of von Willebrand Factor (vWF), which can be obtained by absorbing vWF to a heparin affinity support followed by eluting the vWF at differing salt concentrations.Type: GrantFiled: December 19, 1996Date of Patent: April 6, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner
-
Patent number: 5877274Abstract: A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2 -KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1) and NH.sub.2 -KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO:2).Type: GrantFiled: June 2, 1995Date of Patent: March 2, 1999Assignee: University of British ColumbiaInventors: Robert E. W. Hancock, Nedra Karunaratne
-
Patent number: 5874558Abstract: A process for expression of a protein product in Aspergillus oryzae is disclosed. The process comprises transforming Aspergillus oryzae with a vector system comprising DNA-sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in A. oryzae. Examples of such products are chymosin or prochymosin and other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinant Humicola lipase. The recombinant Humicola lipase from A. oryzae differs from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.Type: GrantFiled: May 17, 1996Date of Patent: February 23, 1999Assignee: Novo NordiskInventors: Esper Boel, Tove Christensen, Helle Fabricius Woldike
-
Patent number: 5874277Abstract: This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including tumor, cerebral apoplexy, cerebral infarction, subarachnoid hemorrhage, Alzheimer's disease, myodystrophy, cataract, ischemic heart disease, atherosclerosis, arthritis, and collagen disease.Type: GrantFiled: April 4, 1997Date of Patent: February 23, 1999Assignee: Takeda Chemical Industries, LtdInventors: Yasushi Shintani, Kazunori Nishi, Tomohiro Kawamoto